Symbicort Turbuhaler信必可

Symbicort Turbuhaler Indications/Uses

budesonide + formoterol

Manufacturer:

AstraZeneca

Distributor:

Zuellig
/
Four Star
The information highlighted (if any) are the most recent updates for this brand.
Full Prescribing Info
Indications/Uses
Asthma: 80/4.5 mcg: Symbicort Turbuhaler 80/4.5 μg/dose is indicated in adults, adolescents, and children aged 6 years and older.
Symbicort Turbuhaler 80/4.5 μg/dose is indicated in the regular treatment of asthma where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate: patients not adequately controlled with inhaled corticosteroids and "as needed" inhaled short-acting β2 adrenoceptor agonists; or patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.
Note: Symbicort (80 micrograms/4.5 micrograms/inhalation) is not appropriate in patients with severe asthma.
160/4.5 mcg: Symbicort Turbuhaler is indicated in adults and adolescents (12 years and older), for the treatment of asthma, to achieve overall asthma control, including the relief of symptoms and the reduction of the risk of exacerbations (see Dosage & Administration).
320/9 mcg: Symbicort Turbuhaler 320/9 μg/dose is indicated in adults, and adolescents aged 12-17 years, for the regular treatment of asthma where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate: patients not adequately controlled with inhaled corticosteroids and "as needed" inhaled short-acting β2 adrenoceptor agonists; or patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.
Chronic Obstructive Pulmonary Disease (COPD): 160/4.5 mcg: Symbicort is indicated for the symptomatic treatment of moderate to severe COPD (FEV1 ≤50% predicted normal) in adults with frequent symptoms despite long-acting bronchodilator use, and/or a history of recurrent exacerbations. Symbicort is not indicated for the initiation of bronchodilator therapy in COPD.
320/9 mcg: Symbicort Turbuhaler 320/9 μg/dose is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with COPD with forced expiratory volume in 1 second (FEV1) <70% predicted normal (post-bronchodilator) and an exacerbation history despite regular bronchodilator therapy (see also Precautions).
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in